Patients with node-negative (N0), ER+, HER2-negative breast cancer and RS <11 are in 7%.

Excluded were those with node-positive disease, prior invasive tumors, or concurrent multiple tumors.

RESULTS

Here, we characterize the BCSS of patients with N0, HR+, HER2-negative breast cancer in the SEER registry who have RS <11 across cancer histopathologic features.

• To determine BCSS of SEER patients with hormone receptor-positive (HR+), HER2-negative, N0 invasive breast cancer and RS <11, by categories of age, tumor size, and tumor grade.

METHODS

• SEER Program of the National Cancer Institute is an authoritative source of cancer incidence and survival statistics, collecting population-based data for ~30% of the US.

• The SEER Program of the National Cancer Institute is an authoritative source of cancer incidence and survival statistics, collecting population-based data for ~30% of the US.

• Since 1977, the American Joint Committee on Cancer (AJCC) Cancer Staging Manual has been the most comprehensive guide to cancer staging.

• The AJCC Cancer Staging Manual 8th edition (2016) added for the first time histologic grade, ER, PR, and HER2 status, and the 21-gene Oncotype DX Breast Recurrence Score (RS) assay results for prognostic staging [1].

• Patients with node-negative (N0), ER+, HER2-negative breast cancer and RS <11 in a prognostic stage (A) are eligible for this analysis, based on the 8th edition AJCC Cancer Staging Manual.

• The 9,000 patients with RS <11 treated with neoadjuvant chemotherapy (NAC) were stage IIA (25%), IIB (24%), and IIB (24%), and 30% were 5 years BCSS.

• Azolaf 6,004 patients with NS, HR+, HER2-negative breast cancer, and HER2-negative breast cancer was classified as prognostic stage IA by the new 8th edition AJCC Staging Manual.

• No central ER, PR, HER2 IHC, or HER2 FISH assessment in patients treated in clinical practice, no randomization to treatment.

LIMITATIONS

• Patients treated in clinical practice, no central ER, PR, HER2 IHC, or HER2 FISH assessment.

• No central ER, PR, HER2 IHC, or HER2 FISH assessment.

• SEER real-world evidence of outcomes of patients treated based on RS results confirm new AJCC 8th edition staging criteria.

• Patients treated in clinical practice, no central ER, PR, HER2 IHC, or HER2 FISH assessment.

• Patients treated in clinical practice, no central ER, PR, HER2 IHC, or HER2 FISH assessment.

• Patients treated in clinical practice, no central ER, PR, HER2 IHC, or HER2 FISH assessment.

• Present at: 40th Annual SABCS; December 5-9, 2017; San Antonio, TX. Poster P1-06-03.

• SABCS 2017 (abstract no. P1-06-03).


• Present at: 40th Annual SABCS; December 5-9, 2017; San Antonio, TX. Poster P1-06-03.

REFERENCES


